Application status of patient-reported outcome scale in lung cancer surgery_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

ZHANG Qi ^1,2 , DAI Wei ² , WEI Xing ² ,  LI Qiang ²

1. Department of Thoracic Surgery, Zigong Third People's Hospital, Zigong, 643021, Sichuan, P. R. China;
2. Department of Thoracic Surgery, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, Affiliated Cancer Hospital of the University of Electronic Science and Technology of China, Chengdu, 610041, P. R. China;

Corresponding author：

LI Qiang, Email: liqiang@sichuancancer.org

Keywords：

Patient-reported outcome; scale; lung cancer surgery; clinical application; review

DOI：

10.7507/1007-4848.202209002

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Patient-reported outcome (PRO) has been paid increasing attention in lung cancer surgery. It has gradually become an important outcome indicator in clinical research of lung cancer surgery and an important tool for symptom management. Commonly used lung cancer-specific PRO measurement tools include: Lung Cancer Symptom Scale, European Organization for Research and Treatment of Cancer-Core Quality of Life Questionnaire and Lung Cancer module, Functional Assessment of Cancer Therapy-Lung, MD Anderson Symptom Inventory-Lung Cancer module, Postoperative Symptom Scale for Lung Cancer Patients, and Perioperative Symptom Assessment for Lung Surgery. The application of lung cancer-specific scales lacks authoritative implementation norms in the field of lung cancer surgery in terms of scale selection, data collection, and outcome application. This review aimed to analyze the current status of application of PRO scales in lung cancer surgery.

Citation： ZHANG Qi, DAI Wei, WEI Xing, LI Qiang. Application status of patient-reported outcome scale in lung cancer surgery. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(4): 606-612. doi: 10.7507/1007-4848.202209002 Copy

1.	Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2.	van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: Latest developments and unanswered questions. Lancet Respir Med, 2016, 4(9): 749-761.
3.	Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction—Evidence, pitfalls and future perspectives. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
4.	Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: Non-small cell lung cancer, version 2. 2021. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
5.	Tandberg DJ, Tong BC, Ackerson BG, et al. Surgery versus stereotactic body radiation therapy for stage Ⅰ non-small cell lung cancer: A comprehensive review. Cancer, 2018, 124(4): 667-678.
6.	Merlo A, Carlson R, Espey J, et al. Postoperative symptom burden in patients undergoing lung cancer surgery. J Pain Symptom Manage, 2022, 64(3): 254-267.
7.	U. S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual Life Outcomes, 2006, 4: 79.
8.	Cleeland CS, Wang XS, Shi Q, et al. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: A randomized controlled clinical trial. J Clin Oncol, 2011, 29(8): 994-1000.
9.	Nipp RD, El-Jawahri A, Ruddy M, et al. Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer. Ann Oncol, 2019, 30(2): 274-280.
10.	Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 2017, 318(2): 197-198.
11.	Barbera L, Sutradhar R, Seow H, et al. The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population-based retrospective matched cohort analysis. Cancer Med, 2020, 9(19): 7107-7115.
12.	Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res, 2013, 13: 211.
13.	Araujo LH, Baldotto CS, Monteiro MR, et al. Patient-centered outcomes in non-small-cell lung cancer: A real-world perspective. Future Oncol, 2021, 17(14): 1721-1733.
14.	Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase Ⅲ CheckMate 227 trial. Eur J Cancer, 2019, 116: 137-147.
15.	Barlesi F, Garon EB, Kim DW, et al. Health-related quality of life in KEYNOTE-010: A phase Ⅱ/Ⅲ study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. J Thorac Oncol, 2019, 14(5): 793-801.
16.	Medbery RL, Fernandez FG, Khullar OV. ERAS and patient reported outcomes in thoracic surgery: A review of current data. J Thorac Dis, 2019, 11(Suppl 7): S976-S986.
17.	Moffatt-Bruce SD. Healthcare systems approach to patient reported outcomes-benefits and challenges in thoracic surgery. J Thorac Dis, 2020, 12(11): 6947-6951.
18.	Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer, 1993, 29A Suppl 1: S51-S58.
19.	Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer, 1994, 73(8): 2087-2098.
20.	Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer, 1999, 7(3): 140-148.
21.	Hollen PJ, Gralla RJ, Stewart JA, et al. Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). Support Care Cancer, 2013, 21(1): 165-172.
22.	Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85(5): 365-376.
23.	Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer, 1994, 30A(5): 635-642.
24.	Koller M, Warncke S, Hjermstad MJ, et al. Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. Cancer, 2015, 121(24): 4300-4323.
25.	Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: A systematic literature review. Health Econ Rev, 2013, 3(1): 15.
26.	Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol, 2011, 29(15): 2104-2120.
27.	de Rooij BH, van den Hurk C, Smaardijk V, et al. Development of an updated, standardized, patient-centered outcome set for lung cancer. Lung Cancer, 2022, 173: 5-13.
28.	Wan C, Zhang C, Tu X, et al. Validation of the simplified Chinese version of the quality of life instrument EORTC QLQ-LC43 for patients with lung cancer. Cancer Invest, 2008, 26(5): 504-510.
29.	Zhang L, Su Y, Hua Y, et al. Validation of EORTC QLQ-LC43 for Chinese patients with lung cancer. Lung Cancer, 2014, 85(1): 94-98.
30.	Koller M, Hjermstad MJ, Tomaszewski KA, et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol, 2017, 28(11): 2874-2881.
31.	Koller M, Shamieh O, Hjermstad MJ, et al. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): An international, observational field study. Lancet Oncol, 2020, 21(5): 723-732.
32.	Koch M, Gräfenstein L, Karnosky J, et al. Psychosocial burden and quality of life of lung cancer patients: Results of the EORTC QLQ-C30/QLQ-LC29 questionnaire and Hornheide screening instrument. Cancer Manag Res, 2021, 13: 6191-6197.
33.	Dai W, Wang Y, Liu Y, et al. Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer. J Patient Rep Outcomes, 2021, 5(1): 122.
34.	Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol, 1993, 11(3): 570-579.
35.	Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer, 1995, 12(3): 199-220.
36.	Cella D. The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin Oncol, 2004, 31(3 Suppl 9): 11-15.
37.	Butt Z, Webster K, Eisenstein AR, et al. Quality of life in lung cancer: The validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am, 2005, 19(2): 389-420.
38.	Yoo H, Suh C, Kim S, et al. Korean translation and validation of the functional assessment of cancer therapy-lung (FACT-L) version 4. Qual Life Res, 2006, 15(1): 161-166.
39.	Saitoh E, Yokomizo Y, Chang CH, et al. Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. J Nippon Med Sch, 2007, 74(6): 402-408.
40.	万崇华, 张灿珍, 宋元龙, 等. 肺癌患者生存质量测定量表FACT-L中文版. 中国肿瘤, 2000, 9(3): 109-110.
41.	Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory. Cancer, 2000, 89(7): 1634-1646.
42.	Mendoza TR, Wang XS, Lu C, et al. Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist, 2011, 16(2): 217-227.
43.	Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: A systematic review. J Clin Oncol, 2006, 24(9): 1459-1473.
44.	Wang XS, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage, 2016, 51(5): 832-838.
45.	Wang XS, Wang Y, Guo H, et al. Chinese version of the M. D. Anderson Symptom Inventory: Validation and application of symptom measurement in cancer patients. Cancer, 2004, 101(8): 1890-1901.
46.	张立力, 臧瑜. MD安德森症状评估量表肺癌模块的修订和考评. 肿瘤, 2013, 33(5): 434-438.
47.	Tang L, Yu H, Dai W, et al. Symptom trajectories informing patient care after lung cancer surgery: A longitudinal patient-reported outcome study. Ann Surg Oncol, 2023, 30(5): 2607-2617.
48.	王明铭, 李霞, 车国卫, 等. 肺癌患者术后症状评估量表的有效性及临床应用. 中国胸心血管外科临床杂志, 2017, 24(6): 417-422.
49.	姚丽, 郑娥, 杨梅, 等. 基于患者报告结局的胸腔镜肺癌切除术后患者症状调查. 中国胸心血管外科临床杂志, 2023, 30(1): 84-88.
50.	28th Annual Conference of the International Society for Quality of Life Research. Qual Life Res, 2021, 30(Suppl 1): 1-177.
51.	Wei X, Yu H, Dai W, et al. Patient-reported outcomes of video-assisted thoracoscopic surgery versus thoracotomy for locally advanced lung cancer: A longitudinal cohort study. Ann Surg Oncol, 2021, 28(13): 8358-8371.
52.	Dai W, Dai Z, Wei X, et al. Early patient-reported outcomes after uniportal vs multiportal thoracoscopic lobectomy. Ann Thorac Surg, 2022, 114(4): 1229-1237.
53.	Gralla RJ. Quality-of-life evaluation in cancer: The past and the future. Cancer, 2015, 121(24): 4276-4278.
54.	Shi Q, Wang XS, Vaporciyan AA, et al. Patient-reported symptom interference as a measure of postsurgery functional recovery in lung cancer. J Pain Symptom Manage, 2016, 52(6): 822-831.
55.	Dai W, Feng W, Zhang Y, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: A multicenter randomized controlled trial. J Clin Oncol, 2022, 40(9): 988-996.
56.	Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res, 2018, 27(5): 1147-1157.
57.	Boyce MB, Browne JP. Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review. Qual Life Res, 2013, 22(9): 2265-2278.
58.	Brønserud MM, Iachina M, Green A, et al. Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study. Lung Cancer, 2019, 128: 67-73.
59.	Heiden BT, Subramanian MP, Liu J, et al. Long-term patient-reported outcomes after non-small cell lung cancer resection. J Thorac Cardiovasc Surg, 2022, 164(3): 615-626.
60.	Avery KNL, Blazeby JM, Chalmers KA, et al. Impact on health-related quality of life of video-assisted thoracoscopic surgery for lung cancer. Ann Surg Oncol, 2020, 27(4): 1259-1271.
61.	Szeliga E, Czenczek-Lewandowska E, Kontek A, et al. Evaluation of the quality of life after surgical removal of lung cancer. Adv Respir Med, 2019, 87(1): 14-19.
62.	Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: A randomised controlled trial. Lancet Oncol, 2016, 17(6): 836-844.
63.	Dai W, Zhang Y, Feng W, et al. Using patient-reported outcomes to manage postoperative symptoms in patients with lung cancer: Protocol for a multicentre, randomised controlled trial. BMJ Open, 2019, 9(8): e030041.
64.	Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol, 2014, 32(14): 1480-1501.
65.	Gundy CM, Aaronson NK. Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: A randomized study. Health Qual Life Outcomes, 2010, 8: 35.
66.	Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol, 2016, 34(6): 557-565.
67.	Pompili C, Brunelli A, Xiumé F, et al. Predictors of postoperative decline in quality of life after major lung resections. Eur J Cardiothorac Surg, 2011, 39(5): 732-737.
68.	Yun YH, Kim YA, Sim JA, et al. Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer. BMC Cancer, 2016, 16: 505.
69.	Xu W, Dai W, Gao Z, et al. Establishment of minimal clinically important improvement for patient-reported symptoms to define recovery after video-assisted thoracoscopic surgery. Ann Surg Oncol, 2022, 29(9): 5593-5604.
70.	戴维, 石丘玲, 李强, 等. 基于患者报告结局的症状管理在肺癌外科的应用现状. 中国胸心血管外科临床杂志, 2020, 27(10): 1228-1234.

1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3): 209-249.
2. van der Aalst CM, Ten Haaf K, de Koning HJ. Lung cancer screening: Latest developments and unanswered questions. Lancet Respir Med, 2016, 4(9): 749-761.
3. Oudkerk M, Liu S, Heuvelmans MA, et al. Lung cancer LDCT screening and mortality reduction—Evidence, pitfalls and future perspectives. Nat Rev Clin Oncol, 2021, 18(3): 135-151.
4. Ettinger DS, Wood DE, Aisner DL, et al. NCCN guidelines insights: Non-small cell lung cancer, version 2. 2021. J Natl Compr Canc Netw, 2021, 19(3): 254-266.
5. Tandberg DJ, Tong BC, Ackerson BG, et al. Surgery versus stereotactic body radiation therapy for stage Ⅰ non-small cell lung cancer: A comprehensive review. Cancer, 2018, 124(4): 667-678.
6. Merlo A, Carlson R, Espey J, et al. Postoperative symptom burden in patients undergoing lung cancer surgery. J Pain Symptom Manage, 2022, 64(3): 254-267.
7. U. S. Department of Health and Human Services FDA Center for Drug Evaluation and Research. Guidance for industry: Patient-reported outcome measures: Use in medical product development to support labeling claims: Draft guidance. Health Qual Life Outcomes, 2006, 4: 79.
8. Cleeland CS, Wang XS, Shi Q, et al. Automated symptom alerts reduce postoperative symptom severity after cancer surgery: A randomized controlled clinical trial. J Clin Oncol, 2011, 29(8): 994-1000.
9. Nipp RD, El-Jawahri A, Ruddy M, et al. Pilot randomized trial of an electronic symptom monitoring intervention for hospitalized patients with cancer. Ann Oncol, 2019, 30(2): 274-280.
10. Basch E, Deal AM, Dueck AC, et al. Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment. JAMA, 2017, 318(2): 197-198.
11. Barbera L, Sutradhar R, Seow H, et al. The impact of routine Edmonton Symptom Assessment System (ESAS) use on overall survival in cancer patients: Results of a population-based retrospective matched cohort analysis. Cancer Med, 2020, 9(19): 7107-7115.
12. Chen J, Ou L, Hollis SJ. A systematic review of the impact of routine collection of patient reported outcome measures on patients, providers and health organisations in an oncologic setting. BMC Health Serv Res, 2013, 13: 211.
13. Araujo LH, Baldotto CS, Monteiro MR, et al. Patient-centered outcomes in non-small-cell lung cancer: A real-world perspective. Future Oncol, 2021, 17(14): 1721-1733.
14. Reck M, Schenker M, Lee KH, et al. Nivolumab plus ipilimumab versus chemotherapy as first-line treatment in advanced non-small-cell lung cancer with high tumour mutational burden: Patient-reported outcomes results from the randomised, open-label, phase Ⅲ CheckMate 227 trial. Eur J Cancer, 2019, 116: 137-147.
15. Barlesi F, Garon EB, Kim DW, et al. Health-related quality of life in KEYNOTE-010: A phase Ⅱ/Ⅲ study of pembrolizumab versus docetaxel in patients with previously treated advanced, programmed death ligand 1-expressing NSCLC. J Thorac Oncol, 2019, 14(5): 793-801.
16. Medbery RL, Fernandez FG, Khullar OV. ERAS and patient reported outcomes in thoracic surgery: A review of current data. J Thorac Dis, 2019, 11(Suppl 7): S976-S986.
17. Moffatt-Bruce SD. Healthcare systems approach to patient reported outcomes-benefits and challenges in thoracic surgery. J Thorac Dis, 2020, 12(11): 6947-6951.
18. Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: Testing the Lung Cancer Symptom Scale (LCSS). Eur J Cancer, 1993, 29A Suppl 1: S51-S58.
19. Hollen PJ, Gralla RJ, Kris MG, et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. Cancer, 1994, 73(8): 2087-2098.
20. Hollen PJ, Gralla RJ, Kris MG, et al. Normative data and trends in quality of life from the Lung Cancer Symptom Scale (LCSS). Support Care Cancer, 1999, 7(3): 140-148.
21. Hollen PJ, Gralla RJ, Stewart JA, et al. Can a computerized format replace a paper form in PRO and HRQL evaluation? Psychometric testing of the computer-assisted LCSS instrument (eLCSS-QL). Support Care Cancer, 2013, 21(1): 165-172.
22. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst, 1993, 85(5): 365-376.
23. Bergman B, Aaronson NK, Ahmedzai S, et al. The EORTC QLQ-LC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. EORTC Study Group on Quality of Life. Eur J Cancer, 1994, 30A(5): 635-642.
24. Koller M, Warncke S, Hjermstad MJ, et al. Use of the lung cancer-specific Quality of Life Questionnaire EORTC QLQ-LC13 in clinical trials: A systematic review of the literature 20 years after its development. Cancer, 2015, 121(24): 4300-4323.
25. Damm K, Roeske N, Jacob C. Health-related quality of life questionnaires in lung cancer trials: A systematic literature review. Health Econ Rev, 2013, 3(1): 15.
26. Claassens L, van Meerbeeck J, Coens C, et al. Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol, 2011, 29(15): 2104-2120.
27. de Rooij BH, van den Hurk C, Smaardijk V, et al. Development of an updated, standardized, patient-centered outcome set for lung cancer. Lung Cancer, 2022, 173: 5-13.
28. Wan C, Zhang C, Tu X, et al. Validation of the simplified Chinese version of the quality of life instrument EORTC QLQ-LC43 for patients with lung cancer. Cancer Invest, 2008, 26(5): 504-510.
29. Zhang L, Su Y, Hua Y, et al. Validation of EORTC QLQ-LC43 for Chinese patients with lung cancer. Lung Cancer, 2014, 85(1): 94-98.
30. Koller M, Hjermstad MJ, Tomaszewski KA, et al. An international study to revise the EORTC questionnaire for assessing quality of life in lung cancer patients. Ann Oncol, 2017, 28(11): 2874-2881.
31. Koller M, Shamieh O, Hjermstad MJ, et al. Psychometric properties of the updated EORTC module for assessing quality of life in patients with lung cancer (QLQ-LC29): An international, observational field study. Lancet Oncol, 2020, 21(5): 723-732.
32. Koch M, Gräfenstein L, Karnosky J, et al. Psychosocial burden and quality of life of lung cancer patients: Results of the EORTC QLQ-C30/QLQ-LC29 questionnaire and Hornheide screening instrument. Cancer Manag Res, 2021, 13: 6191-6197.
33. Dai W, Wang Y, Liu Y, et al. Translation and adaptation of the EORTC QLQ-LC 29 for use in Chinese patients with lung cancer. J Patient Rep Outcomes, 2021, 5(1): 122.
34. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol, 1993, 11(3): 570-579.
35. Cella DF, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer, 1995, 12(3): 199-220.
36. Cella D. The Functional Assessment of Cancer Therapy-Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin Oncol, 2004, 31(3 Suppl 9): 11-15.
37. Butt Z, Webster K, Eisenstein AR, et al. Quality of life in lung cancer: The validity and cross-cultural applicability of the Functional Assessment of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am, 2005, 19(2): 389-420.
38. Yoo H, Suh C, Kim S, et al. Korean translation and validation of the functional assessment of cancer therapy-lung (FACT-L) version 4. Qual Life Res, 2006, 15(1): 161-166.
39. Saitoh E, Yokomizo Y, Chang CH, et al. Cross-cultural validation of the Japanese version of the lung cancer subscale on the functional assessment of cancer therapy-lung. J Nippon Med Sch, 2007, 74(6): 402-408.
40. 万崇华, 张灿珍, 宋元龙, 等. 肺癌患者生存质量测定量表FACT-L中文版. 中国肿瘤, 2000, 9(3): 109-110.
41. Cleeland CS, Mendoza TR, Wang XS, et al. Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory. Cancer, 2000, 89(7): 1634-1646.
42. Mendoza TR, Wang XS, Lu C, et al. Measuring the symptom burden of lung cancer: The validity and utility of the lung cancer module of the M. D. Anderson Symptom Inventory. Oncologist, 2011, 16(2): 217-227.
43. Kirkova J, Davis MP, Walsh D, et al. Cancer symptom assessment instruments: A systematic review. J Clin Oncol, 2006, 24(9): 1459-1473.
44. Wang XS, Shi Q, Williams LA, et al. Prospective study of patient-reported symptom burden in patients with non-small-cell lung cancer undergoing proton or photon chemoradiation therapy. J Pain Symptom Manage, 2016, 51(5): 832-838.
45. Wang XS, Wang Y, Guo H, et al. Chinese version of the M. D. Anderson Symptom Inventory: Validation and application of symptom measurement in cancer patients. Cancer, 2004, 101(8): 1890-1901.
46. 张立力, 臧瑜. MD安德森症状评估量表肺癌模块的修订和考评. 肿瘤, 2013, 33(5): 434-438.
47. Tang L, Yu H, Dai W, et al. Symptom trajectories informing patient care after lung cancer surgery: A longitudinal patient-reported outcome study. Ann Surg Oncol, 2023, 30(5): 2607-2617.
48. 王明铭, 李霞, 车国卫, 等. 肺癌患者术后症状评估量表的有效性及临床应用. 中国胸心血管外科临床杂志, 2017, 24(6): 417-422.
49. 姚丽, 郑娥, 杨梅, 等. 基于患者报告结局的胸腔镜肺癌切除术后患者症状调查. 中国胸心血管外科临床杂志, 2023, 30(1): 84-88.
50. 28th Annual Conference of the International Society for Quality of Life Research. Qual Life Res, 2021, 30(Suppl 1): 1-177.
51. Wei X, Yu H, Dai W, et al. Patient-reported outcomes of video-assisted thoracoscopic surgery versus thoracotomy for locally advanced lung cancer: A longitudinal cohort study. Ann Surg Oncol, 2021, 28(13): 8358-8371.
52. Dai W, Dai Z, Wei X, et al. Early patient-reported outcomes after uniportal vs multiportal thoracoscopic lobectomy. Ann Thorac Surg, 2022, 114(4): 1229-1237.
53. Gralla RJ. Quality-of-life evaluation in cancer: The past and the future. Cancer, 2015, 121(24): 4276-4278.
54. Shi Q, Wang XS, Vaporciyan AA, et al. Patient-reported symptom interference as a measure of postsurgery functional recovery in lung cancer. J Pain Symptom Manage, 2016, 52(6): 822-831.
55. Dai W, Feng W, Zhang Y, et al. Patient-reported outcome-based symptom management versus usual care after lung cancer surgery: A multicenter randomized controlled trial. J Clin Oncol, 2022, 40(9): 988-996.
56. Prinsen CAC, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures. Qual Life Res, 2018, 27(5): 1147-1157.
57. Boyce MB, Browne JP. Does providing feedback on patient-reported outcomes to healthcare professionals result in better outcomes for patients? A systematic review. Qual Life Res, 2013, 22(9): 2265-2278.
58. Brønserud MM, Iachina M, Green A, et al. Patient-reported outcomes (PROs) in lung cancer: Experiences from a nationwide feasibility study. Lung Cancer, 2019, 128: 67-73.
59. Heiden BT, Subramanian MP, Liu J, et al. Long-term patient-reported outcomes after non-small cell lung cancer resection. J Thorac Cardiovasc Surg, 2022, 164(3): 615-626.
60. Avery KNL, Blazeby JM, Chalmers KA, et al. Impact on health-related quality of life of video-assisted thoracoscopic surgery for lung cancer. Ann Surg Oncol, 2020, 27(4): 1259-1271.
61. Szeliga E, Czenczek-Lewandowska E, Kontek A, et al. Evaluation of the quality of life after surgical removal of lung cancer. Adv Respir Med, 2019, 87(1): 14-19.
62. Bendixen M, Jørgensen OD, Kronborg C, et al. Postoperative pain and quality of life after lobectomy via video-assisted thoracoscopic surgery or anterolateral thoracotomy for early stage lung cancer: A randomised controlled trial. Lancet Oncol, 2016, 17(6): 836-844.
63. Dai W, Zhang Y, Feng W, et al. Using patient-reported outcomes to manage postoperative symptoms in patients with lung cancer: Protocol for a multicentre, randomised controlled trial. BMJ Open, 2019, 9(8): e030041.
64. Kotronoulas G, Kearney N, Maguire R, et al. What is the value of the routine use of patient-reported outcome measures toward improvement of patient outcomes, processes of care, and health service outcomes in cancer care? A systematic review of controlled trials. J Clin Oncol, 2014, 32(14): 1480-1501.
65. Gundy CM, Aaronson NK. Effects of mode of administration (MOA) on the measurement properties of the EORTC QLQ-C30: A randomized study. Health Qual Life Outcomes, 2010, 8: 35.
66. Basch E, Deal AM, Kris MG, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol, 2016, 34(6): 557-565.
67. Pompili C, Brunelli A, Xiumé F, et al. Predictors of postoperative decline in quality of life after major lung resections. Eur J Cardiothorac Surg, 2011, 39(5): 732-737.
68. Yun YH, Kim YA, Sim JA, et al. Prognostic value of quality of life score in disease-free survivors of surgically-treated lung cancer. BMC Cancer, 2016, 16: 505.
69. Xu W, Dai W, Gao Z, et al. Establishment of minimal clinically important improvement for patient-reported symptoms to define recovery after video-assisted thoracoscopic surgery. Ann Surg Oncol, 2022, 29(9): 5593-5604.
70. 戴维, 石丘玲, 李强, 等. 基于患者报告结局的症状管理在肺癌外科的应用现状. 中国胸心血管外科临床杂志, 2020, 27(10): 1228-1234.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Application status of patient-reported outcome scale in lung cancer surgery

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content